Back to FDA Approvals

Omnaris Nasal Spray

Generic Name: ciclesonide
Date of Approval: October 20, 2006
Company: Altana Pharma

Treatment for: Allergic Rhinitis

Feedback for Omnaris

0 Comments

Be the first to rate it

The U.S. Food and Drug Administration (FDA) has granted marketing approval for Omnaris (Ciclesonide nasal spray), 200mcg once-daily.

Omnaris is an intranasal corticosteroid containing Ciclesonide as active substance. It is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 12 years of age and older. In addition, the FDA determined Omnaris approvable for the indication in children ages 2 to 11 years of age.

Intranasal corticosteroids are considered to be the gold standard for the treatment of allergic rhinitis, and they work by reducing inflammation - the major underlying cause of nasal symptoms.

About Allergic Rhinitis

Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa causing sneezing, itching, nasal congestion, and discharge. Seasonal allergic rhinitis is caused by substances that trigger allergies and is sometimes referred to as hay fever. Perennial allergic rhinitis is a chronic condition caused by triggers such as pet dander and dust. The result of poorly controlled allergies can result in impairments in day-to-day activities as well as a reduction in a patient's quality of life. According to the American Academy of Allergy, Asthma, and Immunology, more than 40 million Americans are currently estimated to suffer with allergic diseases and allergies are the sixth leading cause of chronic disease in the United States.

For more information, please see Omnaris Product Label (PDF)

Source: Altana